Physician profile
Michael P Cecil
NPI 1821048042
$1,032.74
in general payments reported to CMS, 2019-2025
20 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.12 · 2021: $86.39 · 2022: $201 · 2023: $85.41 · 2024: $233 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.31 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $138.52 | 2021-2025 | |
| Abbott Laboratories | $103.78 | 2022-2025 | Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.04 | 2024-2025 | Lifevest |
| Cvrx, INC. | $76.88 | 2024-2025 | Barostim Neo System |
| Irhythm Technologies, INC. | $70.54 | 2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $68.52 | 2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $66.86 | 2021-2025 | Verquvo |
| Vital Connect, INC | $66.67 | 2022 | |
| Boston Scientific Corporation | $57.58 | 2024 | Varithena Administration Pack |
| Scpharmaceuticals INC. | $48.45 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $48.14 | 2024-2025 | Farxiga, Wainua |
| Pfizer INC. | $45.32 | 2021 | |
| Amgen INC. | $31.57 | 2023-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.57 | 2023 | Jardiance |
| Philips North America LLC | $24.10 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $19.81 | 2025 | Opsumit, Uptravi |
| Biotronik INC. | $16.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.40 | 2021 | |
| Medtronic Vascular, INC. | $13.30 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $7.87 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cecil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.